Skip to main content
Erschienen in: CardioVascular and Interventional Radiology 8/2019

09.05.2019 | Clinical Investigation

Usefulness of a Pretreatment CT-Based Modified RENAL Nephrometry Score in Predicting Renal Function After Cryotherapy for T1a Renal Mass

verfasst von: Yoshiki Asayama, Akihiro Nishie, Yasuhiro Ushijima, Daisuke Okamoto, Koichiro Morita, Seiichiro Takao, Daisuke Kakihara, Keisuke Ishimatsu, Kousei Ishigami, Nobuhiro Fujita, Hiroshi Honda

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated the usefulness of the modified RENAL nephrometry (mRN) scoring system for predicting post-cryotherapy renal function in patients with T1a renal mass.

Patients and Methods

A total of 75 patients with a T1a renal mass were enrolled. The mRN score was determined based on the tumor size, the tumor’s exophytic/endophytic properties, the tumor’s nearness to the collecting system, and the anterior/posterior location of the kidney. The change in the estimated glomerular filtration rate (ΔeGFR) was calculated as follows: ΔeGFR = 100 × ([pretreatment eGFR − eGFR at 6 months after cryotherapy]/pretreatment eGFR). Based on the ΔeGFR results, we classified the patients into two groups: a preserved renal function group (ΔeGFR < 10%) and an impaired renal function group (ΔeGFR ≥ 10%). We then analyzed the relationships between the mRN score and ΔeGFR and between the mRN score and the chronic kidney disease (CKD) stage.

Results

The mean ΔeGFR for all patients was 5.5%. The mRN scores of the preserved renal function group (5.8 ± 0.3) were significantly lower than those of the impaired group (7.4 ± 0.3) (p < 0.001). When the mRN score cutoff value was set at 7 points, the mRN had 67.7% sensitivity, 72.7% specificity, 61.8% positive predictive value (PPV), 76.1% negative predictive value (NPV), and 70.7% accuracy for predicting impaired renal function. For predicting a deterioration of CKD stage, the mRN had 92.9% sensitivity, 67.2% specificity, 39.4% PPV, 97.6% NPV, and 72% accuracy.

Conclusion

Our newly proposed modified RENAL nephrometry score was suggested to be useful for predicting renal function after renal cryotherapy.
Literatur
1.
Zurück zum Zitat Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.CrossRefPubMed Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.CrossRefPubMed
2.
Zurück zum Zitat Georgiades CS, Rodriguez R. Efficacy and safety of percutaneous cryoablation for stage 1A/B renal cell carcinoma: results of a prospective, single-arm, 5-year study. Cardiovasc Interv Radiol. 2014;37:1494–9.CrossRef Georgiades CS, Rodriguez R. Efficacy and safety of percutaneous cryoablation for stage 1A/B renal cell carcinoma: results of a prospective, single-arm, 5-year study. Cardiovasc Interv Radiol. 2014;37:1494–9.CrossRef
3.
Zurück zum Zitat Buy X, Lang H, Garnon J, Sauleau E, Roy C, Gangi A. Percutaneous renal cryoablation: prospective experience treating 120 consecutive tumors. AJR Am J Roentgenol. 2013;201:1353–61.CrossRefPubMed Buy X, Lang H, Garnon J, Sauleau E, Roy C, Gangi A. Percutaneous renal cryoablation: prospective experience treating 120 consecutive tumors. AJR Am J Roentgenol. 2013;201:1353–61.CrossRefPubMed
4.
Zurück zum Zitat Aoun HD, Littrup PJ, Jaber M, Memon F, Adam B, Krycia M, Prus M, et al. Percutaneous cryoablation of renal tumors: is it time for a new paradigm shift? J Vasc Interv Radiol. 2017;28:1363–70.CrossRefPubMed Aoun HD, Littrup PJ, Jaber M, Memon F, Adam B, Krycia M, Prus M, et al. Percutaneous cryoablation of renal tumors: is it time for a new paradigm shift? J Vasc Interv Radiol. 2017;28:1363–70.CrossRefPubMed
5.
Zurück zum Zitat Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182:844–53.CrossRefPubMed Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182:844–53.CrossRefPubMed
6.
Zurück zum Zitat Kopp RP, Liss MA, Mehrazin R, Wang S, Lee HJ, Jabaji R, Mirheydar HS, et al. Analysis of renal functional outcomes after radical or partial nephrectomy for renal masses >/=7 cm using the RENAL score. Urology. 2015;86:312–9.CrossRefPubMed Kopp RP, Liss MA, Mehrazin R, Wang S, Lee HJ, Jabaji R, Mirheydar HS, et al. Analysis of renal functional outcomes after radical or partial nephrectomy for renal masses >/=7 cm using the RENAL score. Urology. 2015;86:312–9.CrossRefPubMed
7.
Zurück zum Zitat Gahan JC, Richter MD, Seideman CA, Trimmer C, Chan D, Weaver M, Olweny EO, et al. The performance of a modified RENAL nephrometry score in predicting renal mass radiofrequency ablation success. Urology. 2015;85:125–9.CrossRefPubMed Gahan JC, Richter MD, Seideman CA, Trimmer C, Chan D, Weaver M, Olweny EO, et al. The performance of a modified RENAL nephrometry score in predicting renal mass radiofrequency ablation success. Urology. 2015;85:125–9.CrossRefPubMed
8.
Zurück zum Zitat Yamanaka T, Yamakado K, Yamada T, Fujimori M, Takaki H, Nakatsuka A, Sakuma H, et al. CT-guided percutaneous cryoablation in renal cell carcinoma: factors affecting local tumor control. J Vasc Interv Radiol. 2015;26:1147–53.CrossRefPubMed Yamanaka T, Yamakado K, Yamada T, Fujimori M, Takaki H, Nakatsuka A, Sakuma H, et al. CT-guided percutaneous cryoablation in renal cell carcinoma: factors affecting local tumor control. J Vasc Interv Radiol. 2015;26:1147–53.CrossRefPubMed
9.
Zurück zum Zitat Global KDI. Kdigo 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1.CrossRef Global KDI. Kdigo 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1.CrossRef
10.
Zurück zum Zitat Park SY, Park BK, Kim CK. Thermal ablation in renal cell carcinoma: what affects renal function? Int J Hyperth. 2012;28:729–34.CrossRef Park SY, Park BK, Kim CK. Thermal ablation in renal cell carcinoma: what affects renal function? Int J Hyperth. 2012;28:729–34.CrossRef
11.
Zurück zum Zitat Campbell SC, Novick AC, Streem SB, Klein E, Licht M. Complications of nephron sparing surgery for renal tumors. J Urol. 1994;151:1177–80.CrossRefPubMed Campbell SC, Novick AC, Streem SB, Klein E, Licht M. Complications of nephron sparing surgery for renal tumors. J Urol. 1994;151:1177–80.CrossRefPubMed
12.
13.
Zurück zum Zitat Weisbrod AJ, Atwell TD, Frank I, Callstrom MR, Farrell MA, Mandrekar JN, Charboneau JW. Percutaneous cryoablation of masses in a solitary kidney. AJR Am J Roentgenol. 2010;194:1620–5.CrossRefPubMed Weisbrod AJ, Atwell TD, Frank I, Callstrom MR, Farrell MA, Mandrekar JN, Charboneau JW. Percutaneous cryoablation of masses in a solitary kidney. AJR Am J Roentgenol. 2010;194:1620–5.CrossRefPubMed
14.
Zurück zum Zitat Turna B, Kaouk JH, Frota R, Stein RJ, Kamoi K, Gill IS, Novick AC. Minimally invasive nephron sparing management for renal tumors in solitary kidneys. J Urol. 2009;182:2150–7.CrossRefPubMed Turna B, Kaouk JH, Frota R, Stein RJ, Kamoi K, Gill IS, Novick AC. Minimally invasive nephron sparing management for renal tumors in solitary kidneys. J Urol. 2009;182:2150–7.CrossRefPubMed
15.
Zurück zum Zitat Wuerzner G, Firsov D, Bonny O. Circadian glomerular function: from physiology to molecular and therapeutical aspects. Nephrol Dial Transplant. 2014;29:1475–80.CrossRefPubMed Wuerzner G, Firsov D, Bonny O. Circadian glomerular function: from physiology to molecular and therapeutical aspects. Nephrol Dial Transplant. 2014;29:1475–80.CrossRefPubMed
Metadaten
Titel
Usefulness of a Pretreatment CT-Based Modified RENAL Nephrometry Score in Predicting Renal Function After Cryotherapy for T1a Renal Mass
verfasst von
Yoshiki Asayama
Akihiro Nishie
Yasuhiro Ushijima
Daisuke Okamoto
Koichiro Morita
Seiichiro Takao
Daisuke Kakihara
Keisuke Ishimatsu
Kousei Ishigami
Nobuhiro Fujita
Hiroshi Honda
Publikationsdatum
09.05.2019
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 8/2019
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-019-02238-1

Weitere Artikel der Ausgabe 8/2019

CardioVascular and Interventional Radiology 8/2019 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.